Ready to accelerate your clinical trial? Visit bioaccess® →

Nicholas Kadysh

Nicholas Kadysh Profile Photo

CEO

With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kadysh is the founder and CEO of PharmAla Biotech, a Toronto-based Life Sciences company focused on the manufacturing and development of MDMA and MDXX-class molecules.

Prior to launching PharmAla in 2020, Nick led government relations and regulatory departments for a number of large corporations, including acting as Head of Corporate Affairs for JUUL Labs, as Government Affairs & Public Policy Leader for General Electric Canada, and as Director of Public Affairs for Red Bull Canada.

Nick gained a deep understanding of government as a campaign and legislative staff member in multiple levels of government prior to joining the corporate sector, most recently directing the Outreach department of the Office of the Leader of the Opposition at Queen’s Park in Toronto. He has also worked as a policy advisor at the Parliament of Canada.

Nick is trilingual (English, French & Russian) and is a graduate of Queen’s University. He lives in East Toronto with his wife, Olga, and two daughters, Milena and Sasha. He is active in non-profit and community initiatives in Toronto, including fundraising for Toronto East General Hospital and as a member of the board for Yonge-Dundas Square.

Nicholas Kadysh, CEO at PharmAla Biotech
113
Sept. 26, 2025

Nicholas Kadysh, CEO at PharmAla Biotech

- Guest: Nicholas Kadysh, CEO of PharmAla Biotech, a company pioneering GMP-grade MDMA production and recognized as a top-performing Canadian market stock in 2023. He also serves as Chair of Psychedelics Canada, leading efforts to strengthen legal and ethical standards and advance government engagement and policy in the psychedelic medicine sector.- Core themes:- Biotech innovation in psychedelic-assisted therapies, with a focus on pharmaceutical-grade MDMA manufacturing and compliance.- The evolving future of psychedelic medicine, including clinical translation, regulatory pathways, and integration into healthcare systems.- Policy and public affairs: how industry standards, advocacy, and government collaboration shape responsible growth and patient access in this emerging field.- Takeaways:- PharmAla’s strategy centers on quality, regulatory rigor, and supply readiness for clinical and potential therapeutic use cases.- Industry maturation depends on robust…